Please assess the completion status of the following clinical trial:

Trial Title: Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Naturally or surgically postmenopausal women, with or without an intact uterus, aged 50 to 75 years of age, inclusive. FSH levels greater than 40 mIU/mL~Exclusion Criteria:~1. Currently taking any estrogen/progesterone hormone replacement therapy (HRT).~2. History of allergy or sensitivity to hydroxyprogesterone caproate, castor oil or any of the constituents of the study medications, or history of any drug hypersensitivity or intolerance~3. Poorly controlled diabetes.~4. History or current evidence of deep vein thrombosis, pulmonary embolism or arterial thromboembolic disease (e.g., stroke, myocardial infarction).~5. Known, suspected, or current history of carcinoma of the breast.~6. Subjects with a past history of breast cancer on aromatase inhibitors or selective estrogen receptor modulators.~7. Known, suspected, or current history of hormone dependent tumor within the last 5 years.~8. Any current or recent (within previous 12 months) genital bleeding of unknown etiology.~9. Receipt of any investigational drug within 30 days.~10. Receipt of any prescription or OTC medications that are known to alter CYP3A4 or CYP3A5 levels (e.g., carbamazepine, St. John's Wort, ketoconazole, rifampin, ritonavir, alprazolam, azithromycin, loratadine, etc.) within 14.~11. Any estrogen, progestin, or selective estrogen receptor modulator (SERM) treatment within specified time windows before the study start, ranging from 2 to 6 months.~12. High blood pressure at the screening evaluation, defined as systolic blood pressure \> 150 mm Hg or diastolic blood pressure \> 90 mm Hg.~13. History of excessive alcohol consumption (on average more than 14 units of alcohol/week) during the past 12 months.~14. Use of tobacco products within 30 days of the start of the study.

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A (Type: EXPERIMENTAL): Subcutaneous (SQ) injection using an autoinjector
- Treatment B (Type: ACTIVE_COMPARATOR): Intramuscular injection (IM) using syringe and needle

Based on this trial design, predict the completion outcome and termination type (if applicable).